Merck & Co., Inc. (NYSE:MRK) Issues Earnings Results

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings data on Thursday. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.09 by $0.40, FiscalAI reports. The firm had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.58 earnings per share.

Here are the key takeaways from Merck & Co., Inc.’s conference call:

• Third-quarter revenue rose 5% to $18.1 billion, while Merck raised the midpoint of its 2026 revenue and EPS guidance to $66.8–$67.3 billion and $2.77–$2.82, respectively.
• Newer products continued to gain traction, including WINREVAIR, whose sales increased 94% to $694 million, and WELIREG, up 58% to $307 million; KEYTRUDA sales also grew 6% to $8.6 billion.
• Management highlighted encouraging pipeline progress, including positive phase III data for sac-TMT in endometrial cancer, favorable results for the individualized cancer vaccine intismeran in melanoma, and positive phase IIb data for tulisokibart in hidradenitis suppurativa.
• Management expects more than $2 billion of 2027 revenue headwinds from generic competition and loss of exclusivity affecting BRIDION, the JANUVIA family, and A​​DEMPAS, while KEYTRUDA growth is expected to moderate ahead of its eventual loss-of-exclusivity period.
• Merck expects 2027 to be another investment year, with operating expenses rising at a mid- to high-single-digit rate as it funds launches and pipeline development; vaccine utilization trends, pricing pressure outside the U.S., and policy changes in Germany remain areas to monitor.

Merck & Co., Inc. Stock Up 3.8%

NYSE:MRK traded up $5.39 on Thursday, hitting $146.32. The stock had a trading volume of 13,434,502 shares, compared to its average volume of 9,881,721. Merck & Co., Inc. has a 1 year low of $82.01 and a 1 year high of $156.92. The firm’s fifty day simple moving average is $146.89 and its two-hundred day simple moving average is $126.49. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a market cap of $360.99 billion, a P/E ratio of 43.90, a price-to-earnings-growth ratio of 6.49 and a beta of 0.21.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Beat-and-raise results supported the stock. Merck lifted its 2026 adjusted earnings outlook, helped by better performance from Keytruda—including the newer Qlex formulation—and recently launched products. The company’s sales forecast was raised to approximately $66.8 billion-$67.3 billion. MRK Q3 earnings and sales beat estimates
• Positive Sentiment: Growth from newer products is helping offset longer-term patent concerns. WINREVAIR revenue rose sharply, reaching about $694 million, while Keytruda and Qlex sales remained resilient. Investors are looking for these products to reduce Merck’s dependence on Keytruda before its expected patent-related erosion later in the decade. Merck revenue up on Keytruda and Winrevair growth
• Positive Sentiment: Oncology pipeline news improved Merck’s growth narrative. Phase 3 data showed KEYTRUDA reduced the risk of disease progression in advanced endometrial cancer, while sacituzumab tirumotecan produced positive late-stage results and received FDA priority review. These developments could expand Merck’s future cancer franchise if approvals and commercialization succeed. Merck Phase 3 endometrial cancer data and FDA review
• Neutral Sentiment: Near-term revenue quality remains mixed. Management indicated that roughly $550 million of quarterly sales benefited from customer-purchase timing, suggesting underlying growth was closer to flat. Merck also warned of generic-drug headwinds in 2027, making pipeline execution increasingly important.
• Negative Sentiment: Patent-cliff and legal risks remain overhangs. Keytruda’s eventual loss of exclusivity remains the central long-term concern, and a law firm announced an investigation into potential securities-law violations related to an October 22 disclosure. No wrongdoing has been established.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Richard Deluca sold 20,784 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $130.43, for a total value of $2,710,857.12. Following the completion of the transaction, the executive vice president directly owned 134,703 shares of the company’s stock, valued at approximately $17,569,312.29. This represents a 13.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on MRK shares. Zacks Research cut Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a research report on Monday, October 19th. UBS Group increased their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Leerink Partners increased their price target on Merck & Co., Inc. from $127.00 to $161.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. BMO Capital Markets raised their price objective on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, August 20th. Finally, Argus lifted their price objective on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Seventeen analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $153.12.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.